JPWO2019207061A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019207061A5 JPWO2019207061A5 JP2020559465A JP2020559465A JPWO2019207061A5 JP WO2019207061 A5 JPWO2019207061 A5 JP WO2019207061A5 JP 2020559465 A JP2020559465 A JP 2020559465A JP 2020559465 A JP2020559465 A JP 2020559465A JP WO2019207061 A5 JPWO2019207061 A5 JP WO2019207061A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nucleic acid
- cationic
- therapeutically active
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18169325.0 | 2018-04-25 | ||
| EP18169325 | 2018-04-25 | ||
| EP18189010 | 2018-08-14 | ||
| EP18189010.4 | 2018-08-14 | ||
| PCT/EP2019/060646 WO2019207061A1 (en) | 2018-04-25 | 2019-04-25 | Cryoprotective agents for particulate formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021522248A JP2021522248A (ja) | 2021-08-30 |
| JPWO2019207061A5 true JPWO2019207061A5 (ru) | 2022-04-28 |
| JP7256824B2 JP7256824B2 (ja) | 2023-04-12 |
Family
ID=66240151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558887A Pending JP2021522228A (ja) | 2018-04-25 | 2019-04-25 | Ｒｎａの送達用の脂質に基づく製剤 |
| JP2020559465A Active JP7256824B2 (ja) | 2018-04-25 | 2019-04-25 | 粒子状製剤用の凍結保護剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558887A Pending JP2021522228A (ja) | 2018-04-25 | 2019-04-25 | Ｒｎａの送達用の脂質に基づく製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210137846A1 (ru) |
| EP (3) | EP3784285B1 (ru) |
| JP (2) | JP2021522228A (ru) |
| KR (2) | KR20210021943A (ru) |
| CN (2) | CN112153986B (ru) |
| AU (2) | AU2019258679B2 (ru) |
| BR (2) | BR112020021054A2 (ru) |
| CA (2) | CA3098262A1 (ru) |
| ES (2) | ES2960936T3 (ru) |
| MX (2) | MX2020011166A (ru) |
| PL (1) | PL3784285T3 (ru) |
| WO (2) | WO2019207061A1 (ru) |
| ZA (1) | ZA202006026B (ru) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6022557B2 (ja) | 2011-06-08 | 2016-11-09 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 切断可能な脂質 |
| AU2012267531B2 (en) | 2011-06-08 | 2017-06-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
| EP3620447B1 (en) | 2012-03-29 | 2021-02-17 | Translate Bio, Inc. | Ionizable cationic lipids |
| JP2016514970A (ja) | 2013-03-14 | 2016-05-26 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａのキャップ効率の定量的評価 |
| HUE042640T2 (hu) | 2013-03-14 | 2019-07-29 | Translate Bio Inc | CFTR-mRNS-készítmények, valamint kapcsolódó eljárások és alkalmazások |
| JP2016515216A (ja) | 2013-03-14 | 2016-05-26 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | メッセンジャーｒｎａのキャップ効率の定量的評価 |
| EA201690588A1 (ru) | 2013-10-22 | 2016-09-30 | Шир Хьюман Дженетик Терапис, Инк. | Доставка мрнк в цнс и ее применение |
| CN112656954A (zh) | 2013-10-22 | 2021-04-16 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
| AU2015266764B2 (en) | 2014-05-30 | 2019-11-07 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| US9943595B2 (en) | 2014-12-05 | 2018-04-17 | Translate Bio, Inc. | Messenger RNA therapy for treatment of articular disease |
| US10471153B2 (en) | 2016-11-10 | 2019-11-12 | Translate Bio, Inc. | Ice-based lipid nanoparticle formulation for delivery of mRNA |
| ES2899323T3 (es) | 2017-02-27 | 2022-03-10 | Translate Bio Inc | Métodos de purificación de ARN mensajero |
| MA49393A (fr) | 2017-06-12 | 2020-04-22 | Translate Bio Inc | Poly(phosphoesters) destinés à l'administration d'acides nucléiques |
| AU2018392716A1 (en) | 2017-12-20 | 2020-06-18 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
| US20210137846A1 (en) * | 2018-04-25 | 2021-05-13 | Ethris Gmbh | Cryoprotective agents for particulate formulations |
| JP7384832B2 (ja) | 2018-05-16 | 2023-11-21 | トランスレイト バイオ， インコーポレイテッド | リボースカチオン性脂質 |
| CN117430538A (zh) | 2018-05-24 | 2024-01-23 | 川斯勒佰尔公司 | 硫酯阳离子脂质 |
| EP3802558B1 (en) | 2018-05-30 | 2024-09-11 | Translate Bio, Inc. | Cationic lipids comprising a steroidal moiety |
| EP3836903B1 (en) * | 2018-08-14 | 2024-05-01 | Ethris GmbH | Lipid-based formulations containing salts for the delivery of rna |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| AU2020206109A1 (en) | 2019-01-07 | 2021-07-29 | Translate Bio, Inc. | Composition and methods for treatment of primary ciliary dyskinesia |
| EP3969584A1 (en) | 2019-05-15 | 2022-03-23 | Translate Bio, Inc. | Methods for purification of messenger rna |
| WO2021072172A1 (en) | 2019-10-09 | 2021-04-15 | Translate Bio, Inc. | Compositions, methods and uses of messenger rna |
| CA3158491A1 (en) | 2019-10-24 | 2021-04-29 | Novago Therapeutics Ag | Novel anti-nogo-a antibodies |
| CA3165388A1 (en) | 2019-12-20 | 2021-06-24 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| EP4110296A1 (en) | 2020-02-25 | 2023-01-04 | Translate Bio, Inc. | Improved processes of preparing mrna-loaded lipid nanoparticles |
| US20230242624A1 (en) | 2020-06-02 | 2023-08-03 | Neurimmune Ag | HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| JPS607932A (ja) * | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソーム懸濁液およびその製法 |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| EP0826063A1 (en) * | 1995-04-25 | 1998-03-04 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
| US6017700A (en) | 1995-08-04 | 2000-01-25 | Bayer Corporation | Cationic oligonucleotides, and related methods of synthesis and use |
| CN100462066C (zh) * | 1997-06-27 | 2009-02-18 | 美国生物科学有限公司 | 药剂的新制剂及其制备和应用方法 |
| TW520294B (en) * | 1998-01-08 | 2003-02-11 | Res Dev Foundation | Stabilization of lipid: DNA formulations during nebulization |
| JP2008501336A (ja) * | 2004-06-02 | 2008-01-24 | ソースフアーム・インコーポレイテツド | Ｒｎａを含有する微小胞およびそのための方法 |
| CN1981044B (zh) * | 2004-06-07 | 2010-05-05 | 普洛体维生物治疗公司 | 包封干扰rna的脂质 |
| LT2578685T (lt) | 2005-08-23 | 2019-06-10 | The Trustees Of The University Of Pennsylvania | Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai |
| WO2008051245A2 (en) * | 2005-12-02 | 2008-05-02 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| CN101370817B (zh) | 2005-12-15 | 2012-08-08 | 国立科学研究中心 | 阳离子寡核苷酸、制备阳离子寡核苷酸的自动化方法及其用途 |
| AU2009305639B2 (en) * | 2008-10-16 | 2016-06-23 | Marina Biotech, Inc. | Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics |
| AU2009311667B2 (en) | 2008-11-07 | 2016-04-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| JP5785168B2 (ja) | 2009-07-31 | 2015-09-24 | エスリス ゲーエムベーハーｅｔｈｒｉｓ ＧｍｂＨ | タンパク質発現用未修飾および修飾ヌクレオチドの組み合わせを有するｒｎａ |
| EP3296398A1 (en) * | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
| DK2709589T3 (en) * | 2011-05-16 | 2017-01-23 | Univ Danmarks Tekniske | Charge release of self-organized nanoparticles |
| EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| GB201118704D0 (en) * | 2011-10-28 | 2011-12-14 | Univ Oxford | Cystic fibrosis treatment |
| RS63244B1 (sr) * | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
| EP3800254A1 (en) | 2012-06-08 | 2021-04-07 | Ethris GmbH | Pulmonary delivery of messenger rna |
| EP2972360B1 (en) * | 2013-03-15 | 2018-03-07 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| US12064484B2 (en) | 2013-06-28 | 2024-08-20 | Ethris Gmbh | Compositions for introducing RNA into cells |
| CA2930602C (en) | 2013-11-18 | 2019-05-28 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for rna delivery |
| EP3110954A1 (en) * | 2014-02-26 | 2017-01-04 | Ethris GmbH | Compositions for gastrointestinal administration of rna |
| CN107207428A (zh) | 2014-11-18 | 2017-09-26 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离阳离子脂质 |
| EP3034539A1 (en) | 2014-12-19 | 2016-06-22 | Ethris GmbH | Compositions for introducing nucleic acid into cells |
| CA2974503A1 (en) | 2015-01-21 | 2016-07-28 | Phaserx, Inc. | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
| EP3247363A4 (en) * | 2015-01-21 | 2018-10-03 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
| WO2018010815A1 (en) * | 2016-07-15 | 2018-01-18 | Biontech Rna Pharmaceuticals Gmbh | Formulation for administration of rna |
| US11583504B2 (en) * | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US20210137846A1 (en) * | 2018-04-25 | 2021-05-13 | Ethris Gmbh | Cryoprotective agents for particulate formulations |
-
2019
- 2019-04-25 US US17/050,440 patent/US20210137846A1/en active Pending
- 2019-04-25 ES ES19718759T patent/ES2960936T3/es active Active
- 2019-04-25 ES ES19718760T patent/ES2960939T3/es active Active
- 2019-04-25 KR KR1020207030471A patent/KR20210021943A/ko unknown
- 2019-04-25 KR KR1020207030470A patent/KR20210022535A/ko unknown
- 2019-04-25 MX MX2020011166A patent/MX2020011166A/es unknown
- 2019-04-25 BR BR112020021054-4A patent/BR112020021054A2/pt unknown
- 2019-04-25 MX MX2020011167A patent/MX2020011167A/es unknown
- 2019-04-25 AU AU2019258679A patent/AU2019258679B2/en active Active
- 2019-04-25 WO PCT/EP2019/060646 patent/WO2019207061A1/en unknown
- 2019-04-25 AU AU2019258678A patent/AU2019258678B2/en active Active
- 2019-04-25 CN CN201980034487.6A patent/CN112153986B/zh active Active
- 2019-04-25 US US17/050,441 patent/US20210137840A1/en not_active Abandoned
- 2019-04-25 JP JP2020558887A patent/JP2021522228A/ja active Pending
- 2019-04-25 EP EP19718760.2A patent/EP3784285B1/en active Active
- 2019-04-25 CA CA3098262A patent/CA3098262A1/en active Pending
- 2019-04-25 BR BR112020021037-4A patent/BR112020021037A2/pt unknown
- 2019-04-25 WO PCT/EP2019/060644 patent/WO2019207060A1/en unknown
- 2019-04-25 JP JP2020559465A patent/JP7256824B2/ja active Active
- 2019-04-25 PL PL19718760.2T patent/PL3784285T3/pl unknown
- 2019-04-25 EP EP23187109.6A patent/EP4311541A3/en active Pending
- 2019-04-25 CN CN201980034447.1A patent/CN112153985B/zh active Active
- 2019-04-25 EP EP19718759.4A patent/EP3784284B1/en active Active
- 2019-04-25 CA CA3098259A patent/CA3098259C/en active Active
-
2020
- 2020-09-29 ZA ZA2020/06026A patent/ZA202006026B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019207061A5 (ru) | ||
| Alhajj et al. | Leucine as an excipient in spray dried powder for inhalation | |
| Son et al. | Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: Effect of spray drying process conditions on aerosol performance | |
| JP2016512494A5 (ru) | ||
| Rajabnezhad et al. | Pulmonary delivery of rifampicin microspheres using lower generation polyamidoamine dendrimers as a carrier | |
| BR112013007304B1 (pt) | Pós secos de cátion de metal monovalente para inalação | |
| CN105188757A (zh) | 多孔载体颗粒和微粒化药物的可吸入团聚物 | |
| JP2002541183A (ja) | 医薬用エアゾール製剤 | |
| JP2012082229A (ja) | 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法 | |
| JP2014224147A5 (ru) | ||
| CN105392471A (zh) | 用于呼吸递送三种或更多种活性剂的组合物、方法和系统 | |
| JP2020518620A (ja) | 肺、鼻、舌下および／または咽頭への送達に適した、少なくとも１つの生物活性化合物をロードした多孔質シリカ粒子の製造方法 | |
| RU2014140539A (ru) | Агрегированные частицы | |
| RU2018112077A (ru) | Направленная доставка высушенных распылением композиций в легкие | |
| JP2016535094A5 (ru) | ||
| Carvalho et al. | Dry powder inhalation for pulmonary delivery: recent advances and continuing challenges | |
| Kanojia et al. | Recent advancements and applications of inhalable microparticles based drug delivery systems in respiratory disorders | |
| PT1259228E (pt) | Composições terapêuticas para distribuição pulmonar | |
| JP5981123B2 (ja) | ニコチン薬の製造法およびその方法により製造される医薬 | |
| CN103347518A (zh) | 含有抗毒蕈碱药物的无推进剂液体制剂 | |
| CN107205936B (zh) | 包含至少一种通过喷雾干燥得到的增加制剂稳定性的干粉的组合物 | |
| JP5501451B2 (ja) | 咳の治療のためのテオブロミン | |
| AU2014352793B2 (en) | An inhalable medicament | |
| WO2021203914A1 (zh) | 一种帕拉米韦干粉吸入剂及其制备方法 | |
| RU2582218C2 (ru) | Способ получения дозирующего распыляющего ингалятора для лечения респираторного заболевания |